Peter Dines
Chief Operating Officer & Head of Life Sciences & Biosciences @ Mercia Asset Management
Four Oaks, United Kingdom
Peter Dines is a Series A investor at Mercia Asset Management in Four Oaks focused on Medical and Health Care. Peter has been involved with a number of high profile turnarounds and exits within the sector, including the acquisition of Surgicraft’s loss making business where, as Managing Director, sales quadrupled within three years and the business was subsequently sold to ISIS Equity Partners. Other key healthcare positions held, both previously andcurrently, include Bridges Ventures, Cisiv, Diagnostic World, Spring Active and Newtech Ortho.
- Total investments:
- 19
- Last investment:
- Lead investor:
- 68%
Last updated:
For AI agents: llms.txt
Industries Peter Dines invests in
Stages Peter Dines invests in
Countries Peter Dines invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 2 (11%)
- Health Care 2 (11%)
- Eyewear 1 (5%)
- Software 1 (5%)
- Biotechnology 1 (5%)
Stage
- Series A 2 (11%)
- Seed 1 (5%)
- Pre-Seed 1 (5%)
- Funding Round 1 (5%)
- Venture - Series Unknown 1 (5%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Locate Bio is a regenerative medicine development company focused on orthobiologics. Locate Bio exists to help surgeons improve the lives of people with debilitating spinal conditions. We are curious about what is possible, but ground all our work in robust scientific evidence. We relentlessly pursue high-value opportunities with clear unmetclinical needs. | $11.6M / Venture - Series Unknown / Apr 29, 2024 | ||
| Axis Spine Technologies is building an expert team to develop highly differentiated products that provide meaningful improvements in patient care. | $12.5M / Series A / Oct 18, 2022 | ||
| Locate Bio is a regenerative medicine development company focused on orthobiologics. Locate Bio exists to help surgeons improve the lives of people with debilitating spinal conditions. We are curious about what is possible, but ground all our work in robust scientific evidence. We relentlessly pursue high-value opportunities with clear unmetclinical needs. | $13.9M / Venture - Series Unknown / Sep 03, 2021 | ||
| Axis Spine operates as a spinal implant company. Following the patenting of new technologies in the field of dynamic stabilisation, Axis Spine Ltd was put on hold whilst Jon launched ApaTech's Actifuse product and then NuVasive’s extensive range of spinal products, including XLIF, into the UK market. After successfully accomplishing thesegoals, Jon is now building a team to deliver interesting new technologies that provide the surgeon and hospital payer with improved solutions that represent better value to existing problems. | $2.8M / Feb 24, 2021 | ||
| Axis Spine Technologies is building an expert team to develop highly differentiated products that provide meaningful improvements in patient care. | $3M / Seed / Jan 27, 2021 | ||
| Locate Bio is a regenerative medicine development company focused on orthobiologics. Locate Bio exists to help surgeons improve the lives of people with debilitating spinal conditions. We are curious about what is possible, but ground all our work in robust scientific evidence. We relentlessly pursue high-value opportunities with clear unmetclinical needs. | $2.8M / Venture - Series Unknown / Jul 20, 2020 | ||
| Axis Spine operates as a spinal implant company. Following the patenting of new technologies in the field of dynamic stabilisation, Axis Spine Ltd was put on hold whilst Jon launched ApaTech's Actifuse product and then NuVasive’s extensive range of spinal products, including XLIF, into the UK market. After successfully accomplishing thesegoals, Jon is now building a team to deliver interesting new technologies that provide the surgeon and hospital payer with improved solutions that represent better value to existing problems. | $1.1M / Apr 20, 2020 | ||
| Axis Spine Technologies is building an expert team to develop highly differentiated products that provide meaningful improvements in patient care. | $967K / Seed / Mar 21, 2020 | ||
| Locate Bio is a regenerative medicine development company focused on orthobiologics. Locate Bio exists to help surgeons improve the lives of people with debilitating spinal conditions. We are curious about what is possible, but ground all our work in robust scientific evidence. We relentlessly pursue high-value opportunities with clear unmetclinical needs. | $659.4K / Venture - Series Unknown / Oct 16, 2018 | ||
| Aston EyeTech is a tech startup developing a range of proprietary hardware and software products for ocular care. It is revolutionizing the Ocular care ecosystem through increased portability, improved accuracy, and lower costs.The company is a spinout from Aston University’s School of Optometry. Aston EyeTech was founded in 2014 and is based inBirmingham, England. | $6.6M / Series A / Nov 17, 2017 | ||
| See all 19 investments → | |||
Co-Investors
About Mercia Asset Management
Mercia Asset Management invest across four distinct asset classes of venture, private equity and debt, referred to as our ‘Complete Capital Solution.Mercia Asset Management ision is to be the first choice for investors, investees and employees and, by aspiring to be the first choice, we believe that Mercia will deliver superior returns for business owners, shareholders and fund investors alike.
Mercia Asset Management Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Aaron Lawson-Clark
Investment Director
|
|||
Ashwin Kumaraswamy
Investment Director
|
|||
Brijesh Roy
Investment Manager
|
|||
Clive Downward
Investment Director
|
|||
Graham Davies
Investment Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Peter Dines invest in?
Peter Dines invests primarily in Medical, Health Care and Eyewear startups, most often at Series A and Seed stage. Most of the 19 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Peter Dines?
Public channels for Peter Dines include LinkedIn, X (Twitter) and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Peter Dines last invest?
The most recent investment recorded for Peter Dines closed in Apr 2024. Shizune tracks 19 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
